Verastem (VSTM) Cut to “Strong Sell” at ValuEngine
Verastem (NASDAQ:VSTM) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday.
Other equities analysts also recently issued reports about the stock. Roth Capital assumed coverage on shares of Verastem in a report on Friday. They set a “buy” rating and a $12.00 target price for the company. Cann restated a “buy” rating and set a $6.00 target price on shares of Verastem in a report on Tuesday, November 7th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Verastem in a report on Wednesday, November 8th. Oppenheimer restated a “buy” rating and set a $6.00 target price on shares of Verastem in a report on Wednesday, September 6th. Finally, Cantor Fitzgerald upgraded shares of Verastem from a “neutral” rating to an “overweight” rating and set a $2.00 target price for the company in a report on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $7.78.
Verastem (VSTM) traded down $0.07 during trading hours on Friday, reaching $4.14. 928,671 shares of the company’s stock traded hands, compared to its average volume of 761,373. The company has a quick ratio of 3.12, a current ratio of 3.12 and a debt-to-equity ratio of 0.06. Verastem has a 52-week low of $1.05 and a 52-week high of $5.71.
Hedge funds and other institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new stake in shares of Verastem during the third quarter worth about $136,000. Citadel Advisors LLC purchased a new stake in shares of Verastem during the third quarter worth about $195,000. Alpine Woods Capital Investors LLC purchased a new stake in shares of Verastem during the second quarter worth about $109,000. Northern Trust Corp grew its holdings in shares of Verastem by 40.3% during the second quarter. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 21,178 shares in the last quarter. Finally, Susquehanna International Group LLP grew its holdings in shares of Verastem by 137.1% during the third quarter. Susquehanna International Group LLP now owns 75,526 shares of the biopharmaceutical company’s stock worth $355,000 after buying an additional 43,675 shares in the last quarter. Institutional investors and hedge funds own 34.24% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/01/verastem-vstm-cut-to-strong-sell-at-valuengine.html.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.